A.M. Liberati

957 total citations
32 papers, 606 citations indexed

About

A.M. Liberati is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, A.M. Liberati has authored 32 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 11 papers in Hematology and 10 papers in Oncology. Recurrent topics in A.M. Liberati's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). A.M. Liberati is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). A.M. Liberati collaborates with scholars based in Italy, United States and France. A.M. Liberati's co-authors include Roberto Gerli, Renato Vanacore, F. Greco, Fabrizio Lombardini, G. Longombardo, A. Moretti, L La Civita, E Marzo, Cássia Ferri and Mario Lazzarino and has published in prestigious journals such as Blood, Annals of Oncology and Leukemia.

In The Last Decade

A.M. Liberati

32 papers receiving 577 citations

Peers

A.M. Liberati
Andrew R. Baldassare United States
Barbara Pivetta Italy
Conn Dl United States
Jean‐Charles Piette France
Eléna Foïs France
C. Fellbaum Germany
Yukiko Komano Japan
Orlando Gabriel Carballo Argentina
Larissa Verda United States
Ippei Miyagawa Japan
Andrew R. Baldassare United States
A.M. Liberati
Citations per year, relative to A.M. Liberati A.M. Liberati (= 1×) peers Andrew R. Baldassare

Countries citing papers authored by A.M. Liberati

Since Specialization
Citations

This map shows the geographic impact of A.M. Liberati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.M. Liberati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.M. Liberati more than expected).

Fields of papers citing papers by A.M. Liberati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.M. Liberati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.M. Liberati. The network helps show where A.M. Liberati may publish in the future.

Co-authorship network of co-authors of A.M. Liberati

This figure shows the co-authorship network connecting the top 25 collaborators of A.M. Liberati. A scholar is included among the top collaborators of A.M. Liberati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.M. Liberati. A.M. Liberati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bringhen, Sara, Nicola Giuliani, A.M. Liberati, et al.. (2016). CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY. Haematologica. 101(1). 520–520. 1 indexed citations
2.
Bringhen, Sara, Lorenzo De Paoli, Alessandra Larocca, et al.. (2016). WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). 2–2. 2 indexed citations
3.
Crump, M., Adriana Scheliga, Jiří Mayer, et al.. (2011). Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy. Annals of Oncology. 22. 186–186. 1 indexed citations
4.
Kimby, Eva, Adriana Scheliga, Jiří Mayer, et al.. (2011). FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation. Annals of Oncology. 22. 187–187. 1 indexed citations
5.
Herbrecht, Raoul, A.M. Liberati, Javier Loscertales, et al.. (2009). Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study. Lund University Publications (Lund University). 94. 355–355. 1 indexed citations
6.
7.
Tirelli, Umberto, Michele Spina, Ulrich Jaeger, et al.. (2002). Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study. Recent results in cancer research. 159. 149–153. 32 indexed citations
8.
Russo, Domenico, I Iacona, Stefano Sacchi, et al.. (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling. Clinical Drug Investigation. 16(1). 25–33. 2 indexed citations
9.
Sacchi, Stefano, L Gugliotta, Federico Papineschi, et al.. (1998). Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Leukemia. 12(3). 289–294. 16 indexed citations
10.
Ferrajoli, Alessandra, A.M. Liberati, Emilio Donti, et al.. (1995). Interferon‐α plus low‐dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European Journal Of Haematology. 55(3). 184–188. 9 indexed citations
11.
Liberati, A.M., Michel A. Horisberger, Verena De Angelis, et al.. (1994). Interferon-α-Induced Biologic Modifications in Patients with Chronic Myelogenous Leukemia. Journal of Interferon Research. 14(6). 349–355. 9 indexed citations
12.
Liberati, A.M., Verena De Angelis, Francesco Clemente, et al.. (1994). Double-Blind Randomized Phase I Study on the Clinical Tolerance and Pharmacodynamics of Natural and Recombinant Interferon-β Given Intravenously. Journal of Interferon Research. 14(2). 61–69. 18 indexed citations
13.
Ferri, Cássia, E Marzo, G. Longombardo, et al.. (1993). Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 81(5). 1132–1136. 215 indexed citations
14.
Alimena, Giuliana, Enrica Morra, Mario Lazzarino, et al.. (1991). IL TRATTAMENTO DELLA LEUCEMIA MIELOIDE CRONICA (LMC) CON INTERFERONE ∅-2B (IFN ∅2B). Haematologica. 76. 50. 1 indexed citations
15.
Liberati, A.M., et al.. (1990). Electrophysiological and Neuropsychological Functions in Patients Treated with Interferon-β. Journal of Interferon Research. 10(6). 613–619. 8 indexed citations
16.
Liberati, A.M., Marco Fizzotti, Maria Grazia Proietti, et al.. (1988). Biochemical Host Response to Interferon-β. Journal of Interferon Research. 8(6). 765–777. 16 indexed citations
17.
Alimena, Giuliana, Enrica Morra, Mario Lazzarino, et al.. (1988). Treatment of Ph′-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (INTRON A). Cancer Treatment Reviews. 15. 21–26. 3 indexed citations
18.
Liberati, A.M., et al.. (1985). Thymic hormones II. International Journal of Immunopharmacology. 7(4). 621–621. 1 indexed citations
19.
Liberati, A.M., et al.. (1985). Interferon and inducers. International Journal of Immunopharmacology. 7(4). 616–616. 1 indexed citations
20.
Liberati, A.M., Joseph G. Voelkel, Ernest C. Borden, et al.. (1982). Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma. Cancer Immunology Immunotherapy. 13(2). 140–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew R. Baldassare Breakdown of academic impact, for papers by Barbara Pivetta Breakdown of academic impact, for papers by Conn Dl Breakdown of academic impact, for papers by Jean‐Charles Piette Breakdown of academic impact, for papers by Eléna Foïs Breakdown of academic impact, for papers by C. Fellbaum Breakdown of academic impact, for papers by Yukiko Komano Breakdown of academic impact, for papers by Orlando Gabriel Carballo Breakdown of academic impact, for papers by Larissa Verda Breakdown of academic impact, for papers by Ippei Miyagawa
Rankless by CCL
2026